Corrigendum to “A narrative review of approved and emerging anti-obesity medications” [Saudi Pharm. J. 31(10) (2023) 101757]

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Saudi Pharmaceutical Journal Pub Date : 2024-04-05 DOI:10.1016/j.jsps.2024.102047

Semira Abdi Beshir , Asim Ahmed Elnour , Aadith Soorya , Affana Parveen Mohamed , Sheron Sir Loon Goh , Nadia Hussain , Amal H.I. Al Haddad , Faizah Hussain , Israa Yousif EL Khidir , Zainab Abdelnassir

引用次数: 0

查看原文本刊更多论文

对 "已获批准和新出现的抗肥胖药物的叙述性综述 "的更正[《沙特药学杂志》31(10) (2023) 101757]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Saudi Pharmaceutical Journal PHARMACOLOGY & PHARMACY-

CiteScore

6.10

自引率

2.40%

发文量

194

审稿时长

67 days

期刊介绍： The Saudi Pharmaceutical Journal (SPJ) is the official journal of the Saudi Pharmaceutical Society (SPS) publishing high quality clinically oriented submissions which encompass the various disciplines of pharmaceutical sciences and related subjects. SPJ publishes 8 issues per year by the Saudi Pharmaceutical Society, with the cooperation of the College of Pharmacy, King Saud University.